Drug Trial Radar · NCT05171855
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Dec 16, 2021
Primary completion
Dec 23, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/SIndustry
- Sponsor type
- Industry
- First posted
- Dec 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 23 years, up to 81 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).
Conditions
- Adult Growth Hormone Deficiency
- Endocrine System Diseases
- Hormone Deficiency
Interventions
LonapegsomatropinDrug
Study participants were individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study DiscontinuationTime frame: Up to 52 Weeks
Locations
85 sites in 21 countries. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Phoenix, Arizona
Ascendis Pharma Investigational Site
Torrance, California
Ascendis Pharma Investigational Site
Chicago, Illinois
Ascendis Pharma Investigational Site
Indianapolis, Indiana
Ascendis Pharma Investigational Site
Boston, Massachusetts
Ascendis Pharma Investigational Site
Dearborn, Michigan
Ascendis Pharma Investigational Site
Rochester, Minnesota
Ascendis Pharma Investigational Site
St Louis, Missouri
Ascendis Pharma Investigational Site
Las Vegas, Nevada
Ascendis Pharma Investigational Site
Reno, Nevada
Ascendis Pharma Investigational Site
New York, New York
Ascendis Pharma Investigational Site
Portland, Oregon
Ascendis Pharma Investigational Site
Dallas, Texas
Ascendis Pharma Investigational Site
San Antonio, Texas
Ascendis Pharma Investigational Site
Seattle, Washington
Ascendis Pharma Investigational Site
Yerevan, Armenia
Ascendis Pharma Investigational Site
Saint Leonards, New South Wales, Australia
Ascendis Pharma Investigational Site
Sydney, New South Wales, Australia
Ascendis Pharma Investigational Site
Box Hill, Victoria, Australia
Ascendis Pharma Investigational Site
Fitzroy, Victoria, Australia
Ascendis Pharma Investigational Site
Parkville, Victoria, Australia
Ascendis Pharma Investigational Site
Perth, Western Australia, Australia
Ascendis Pharma Investigational Site
Halifax, Nova Scotia, Canada
Ascendis Pharma Investigational Site
Lyon, France
Ascendis Pharma Investigational Site
Marseille, France
Ascendis Pharma Investigational Site
Nantes, France
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
München, Germany
Ascendis Pharma Investigational Site
Athens, Greece
Ascendis Pharma Investigational Site
Thessaloniki, Greece
Ascendis Pharma Investigational Site
Haifa, Israel
Ascendis Pharma Investigational Site
Petah Tikva, Israel
Ascendis Pharma Investigational Site
Tel Aviv, Israel
Ascendis Pharma Investigational Site
Genova, Italy
Ascendis Pharma Investigational Site
Rome, Italy
Ascendis Pharma Investigational Site
Rome, Italy
Ascendis Pharma Investigational Site
Chiba, Japan
Ascendis Pharma Investigational Site
Fukuoka, Japan
Ascendis Pharma Investigational Site
Ishikawa, Japan
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.